3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Gastrointestinal Stromal Tumors
71
Sarcoma
12
Brain Neoplasms
10
Gliosarcoma
9
Glioblastoma
9
Neoplasm Metastasis
6
Glioma
6
Dermatofibrosarcoma
6
Oligodendroglioma
5
Central Nervous System Neoplasms
5
Astrocytoma
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Fibrosarcoma
4
Chordoma
4
Sarcoma, Synovial
3
Osteosarcoma
3
Neurofibrosarcoma
3
Neuroectodermal Tumors, Primitive, Peripheral
3
Neoplasms
3
Liposarcoma
3
Hemangiosarcoma
3
Glioma, Subependymal
3
Digestive System Neoplasms
3
Desmoid Tumors
3
Sarcoma, Endometrial Stromal
2
Recurrence
2
Primary Myelofibrosis
2
Piebaldism
2
Multiple Myeloma
2
Meningioma
2
Interventions
apatinib
4
Ifosfamide
2
Filgrastim
2
Etoposide
2
selinexor
1
glucarpidase
1
camrelizumab
1
Vincristine
1
Radiotherapy
1
Procarbazine
1
Pharmaceutical Preparations
1
Methotrexate
1
Lomustine
1
Imatinib Mesylate
1
Genetic Therapy
1
Fibroblast Growth Factor 7
1
Drug Combinations
1
Cyclophosphamide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Drug-Related Side Effects and Adverse Reactions
×
Imatinib Mesylate
×
Sarcoma
×
Clear all
NCT04138381
2023-03-27
SeliGIST
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2
Unknown
30 enrolled